Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NQM4
UPID:
DAAF6_HUMAN
Alternative names:
PIH1 domain-containing protein 3; Sarcoma antigen NY-SAR-97
Alternative UPACC:
Q9NQM4; D3DUX5; Q86WE1
Background:
Dynein axonemal assembly factor 6, also known as PIH1 domain-containing protein 3 and Sarcoma antigen NY-SAR-97, plays a crucial role in the cytoplasmic pre-assembly of axonemal dynein. This protein is pivotal for the proper function and structure of motile cilia, which are essential for fluid movement across cell surfaces.
Therapeutic significance:
Given its involvement in primary ciliary dyskinesia, particularly Ciliary dyskinesia, primary, 36, X-linked, understanding the role of Dynein axonemal assembly factor 6 could open doors to potential therapeutic strategies. This condition leads to severe respiratory infections and can result in situs inversus in some patients, highlighting the protein's significance in disease.